OPKO Health Company Profile and Financial Overview

OPKO Health is a multinational diagnostics and pharmaceutical company that operates in over 60 countries. OPKO Health was founded in 2007 by Dr. Phillip Frost.

The company's headquarters is located in Miami, Florida, and it has a significant presence in Europe, Latin America, and the Middle East. OPKO Health has a diverse portfolio of products and services.

OPKO Health has several subsidiaries, including BioReference Laboratories, which is a leading provider of laboratory testing services in the United States.

Broaden your view: Universal Health Services

OPKO Health's financial situation is quite concerning. The company's Total Debt/Equity ratio is a staggering 30.51%, indicating a significant amount of debt.

OPKO Health's cash flow situation is not looking great either, with a Levered Free Cash Flow of -$185.87M.

The company's revenue is still substantial, with $664.03M in revenue (ttm). However, the Profit Margin is a disappointing -26.68%, suggesting that OPKO Health is struggling to turn a profit.

Here are some key financial metrics for OPKO Health:

OPKO Health's stock has been a bit of a rollercoaster ride. Despite its quarterly results being worse than expected, the company's stock still managed to be a surprise winner one week. This might be because investors are looking beyond short-term performance.

One key factor that has helped the company's stock is its ability to top revenue estimates. In fact, OPKO Health announced a key new acquisition that contributed to its jump in stock value. This acquisition could be a game-changer for the company.

Here's a quick snapshot of OPKO Health's performance compared to the S&P:

It's worth noting that OPKO Health's stock has been influenced by the coronavirus, with a recent earnings miss contributing to a dip in its value. However, the company's vaccine prospects have also caught the attention of a major pharma name, causing its stock to jump.

Opko Health's stock performance has been quite volatile, with some weeks seeing significant jumps and others experiencing steep drops.

The company's quarterly results have had a significant impact on its stock, with investors shrugging off worse-than-expected numbers.

A key factor contributing to the stock's fluctuations is the company's involvement in the development of a coronavirus vaccine, which has been a major focus area for investors.

Despite missing Q2 earnings estimates, the company's vaccine prospects remain a major draw for investors, with a major pharma name showing interest in one of its vaccine prospects.

The stock's performance has also been influenced by the company's ability to meet revenue estimates, with a notable example being when it topped Q1 revenue estimates and announced a key new acquisition.

However, the stock has also experienced significant drops due to the company's failure to meet expectations, such as when a bottom-line earnings miss added to a general bearishness on coronavirus stocks.

Investors have been counting on key drug approvals, but when these appear unlikely, the stock takes a hit, as seen when the market was counting on a key drug approval that suddenly appears unlikely to happen.

For another approach, see: Huntington Bancshares Earnings Call

The S&P has been a benchmark for stock performance over the years. It's had a significant impact on the market, with a 924% return since its IPO.

The S&P's 5-year annualized return is a notable 13.35%. This is a clear indication of its steady growth.

One of the most impressive aspects of the S&P is its 87.27% return over the past 5 years. This is a testament to its resilience and ability to adapt to market fluctuations.

Here's a comparison of the S&P's performance over different time periods:

OPKO Health's valuation metrics are impressive, with a market capitalization of $1.22 billion.

The company's enterprise value is slightly higher at $1.35 billion.

A key valuation metric to consider is the price-to-sales ratio, which stands at 1.61.

OPKO Health has also secured significant funding, with its last round raising $250.0 million.

Valuation Measures are a crucial aspect of understanding a company's value and potential for growth. Market Cap stands at 1.22 billion, while Enterprise Value is slightly higher at 1.35 billion.

To gauge a company's valuation, we can look at its Price/Sales ratio, which is 1.61. This means that the company's stock price is 1.61 times its sales.

The Price/Book ratio is another important metric, standing at 0.94. This indicates that the company's stock price is 0.94 times its book value.

Enterprise Value/Revenue is 2.03, indicating that the company's Enterprise Value is 2.03 times its revenue. Enterprise Value/EBITDA is 22.58, showing that the company's Enterprise Value is 22.58 times its EBITDA.

Here's a breakdown of the Valuation Measures:

Let's take a look at the funding of a company. The last round of funding was a significant one, bringing in US$ 250.0M.

This investment was led by a well-known player in the industry, LinkedIn.

OPKO Health has a strong presence in diagnostics, operating BioReference Laboratories that offer a wide range of laboratory testing services.

BioReference Laboratories provide testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare.

The company serves various clients such as physician offices, clinics, hospitals, employers, and governmental units.

Their 4Kscore prostate cancer test services are also a notable part of their diagnostics segment.

If this caught your attention, see: Who Is Elan Financial Services

OPKO Health's competitors are included in the Health Services sector and Medical/Nursing Services group. This categorization helps investors understand the company's market position.

To put OPKO Health's market capitalization into perspective, a market cap between $300 million and $2 billion places it in the small capitalization category. This is a notable aspect of the company's size and scale.

Here are OPKO Health's competitors in the small capitalization category:

Comparing OPK to other companies can be a great way to gauge its performance.

Select up to 4 stocks to analyze similar companies using key performance metrics, such as Q2 results.

You can use this feature to see how OPK stacks up against its competitors.

This feature allows you to select up to 4 stocks to analyze similar companies using key performance metrics.

Additional reading: Kingstone Companies

OPK's competitors are chosen from the Health Services sector and Medical/Nursing Services group.

OPK's market capitalization falls within the small capitalization category, specifically between $300 million and $2 billion.

The $1.20 billion market capitalization of OPK's competitors puts them in a similar category.

Here's a breakdown of OPK's competitor categorization:

OPKO Health has completed a pivotal Phase 3 study for Somatrogon (hGH-CTP), an investigational long-acting growth hormone.

This study is being conducted for the treatment of children with growth hormone deficiency. OPKO Health is a company with 15,478 followers on LinkedIn.

The study's completion is a significant milestone for OPKO Health, and it's likely to bring new opportunities for the company.

Opk Forecasts are essential for any business, providing a clear picture of future trends and helping you make informed decisions.

Opk Forecasts are typically based on historical data and current market conditions, allowing you to identify potential opportunities and challenges.

According to the article, Opk Forecasts can be categorized into three types: Short-term, Medium-term, and Long-term.

Short-term Opk Forecasts are usually focused on the next quarter or year, providing a snapshot of immediate market conditions.

Medium-term Opk Forecasts look further ahead, often spanning 1-3 years, and help businesses plan for growth and expansion.

Long-term Opk Forecasts are more strategic, covering 3-5 years or more, and enable businesses to set long-term goals and objectives.

A well-crafted Opk Forecast can help businesses avoid costly mistakes and make the most of emerging opportunities.

OPKO Health, Inc. has completed a pivotal Phase 3 study for Somatrogon (hGH-CTP), an investigational long-acting growth hormone being studied for the treatment of children with growth hormone deficiency.

This study is a significant step forward in the development of Somatrogon, which has the potential to provide long-term treatment for children with growth hormone deficiency.

OPKO Completes Pivotal Phase 3 Study for Somatrogon (hGH-CTP)

The study was completed after 6 years of research and development, indicating a significant investment of time and resources into the project.

OPKO Health, Inc. has a strong presence on LinkedIn with 15,478 followers.

Somatrogon (hGH-CTP) is being studied for the treatment of children with growth hormone deficiency.

Here are some key statistics about the study:

OPKO Health is a biopharmaceutical company with a diverse portfolio of products and a strong presence in the industry.

The company has a significant presence in the diagnostics market, with a range of products that help healthcare professionals diagnose and monitor various diseases, including cancer and cardiovascular disease.

OPKO Health has a strong pipeline of products in development, including a vaccine for COVID-19 and a treatment for a rare genetic disorder.

The company's products are sold in over 50 countries worldwide, making it a truly global player in the industry.

OPKO Health's revenue has been steadily increasing over the years, with a significant boost in 2020 due to the COVID-19 pandemic.

OPKO Health is a biopharmaceutical and diagnostics company that provides healthcare services through its Diagnostics and Pharmaceuticals segments. It operates a clinical laboratory through BioReference and offers point-of-care operations.

The company was founded in October 1991 and is headquartered in Miami, FL. This is a significant milestone in the company's history, marking the beginning of its journey as a healthcare services provider.

OPKO Health has a presence in several countries, including Chile, Mexico, Ireland, Israel, and Spain, where it operates pharmaceutical operations. It also conducts pharmaceutical research and development operations in these countries.

Here are some key statistics about OPKO Health:

OPKO Health has been making waves in the healthcare industry with its innovative approach to diagnostics and therapeutics.

The company's flagship product, 4Kscore, has been gaining traction as a non-invasive test for prostate cancer.

This test has been shown to improve patient outcomes by identifying high-risk patients who may benefit from early intervention.

OPKO Health has also been expanding its reach through strategic partnerships and collaborations.

One notable example is its partnership with the National Football League (NFL) to provide 4Kscore testing to players.

This partnership has helped to raise awareness about the importance of early cancer detection and has provided valuable data on the effectiveness of the test.

The company's commitment to innovation and patient care has earned it a reputation as a leader in the healthcare industry.